Methylene Blue Liver Safety: What 2026 Research Shows

By NooBlue Editorial · Published August 7, 2026 · Last updated August 7, 2026

A single 500 mg oral dose. That is what healthy volunteers swallowed in the phase I trial most often cited in methylene blue liver research — one hundred times the 5 mg in a standard NooBlue capsule. That gap explains most of the confusion around this question. Nearly everything published on methylene blue and the liver comes from hospital medicine: transplant theatres, poisoning cases, intensive care. Very little of it describes what a low-dose oral supplement does. Here is what the evidence actually supports, and where it runs out.

What Methylene Blue Liver Metabolism Actually Involves

Methylene blue is a redox-active molecule. In tissue it cycles between its blue oxidised form and a colourless reduced form, leucomethylene blue, and that shuttling is the basis of nearly every effect attributed to it. Elimination happens through both the kidneys and the liver, and the reduced form is what mostly leaves the body in urine.

The most useful human data on how much of an oral dose reaches circulation comes from a phase I crossover study in 16 healthy volunteers, published in the European Journal of Clinical Pharmacology. Participants received 50 mg intravenously and 500 mg orally a week apart. Absolute oral bioavailability was 72.3 ± 23.9% (Walter-Sack et al., 2009, PMID 18810398).

That number cuts both ways. High absorption is why an oral capsule can do anything at all. It is also why the systemic load is real rather than theoretical, and why clearance capacity is worth thinking about. The same study found that co-administering chloroquine significantly raised methylene blue plasma concentrations, which is a reminder that other compounds can change how much of it is circulating at once.

None of that makes the compound hepatotoxic. It means the liver is one of the organs involved in handling it, in the same ordinary sense that applies to caffeine or paracetamol. If you want the wider picture rather than the organ-specific one, the full methylene blue side effects guide covers the effects that actually show up in practice, and what methylene blue does to blood pressure answers the other common organ-system question.

How Supplement Doses Compare With the Doses in Liver Research

This is the step almost every article on the topic skips, and it is the one that resolves the question. Below, every figure is normalised to milligrams of methylene blue per single administration, so the rows are directly comparable.

Read the table again and the framing problem becomes obvious. When a study describes methylene blue in the context of liver failure, transplantation or poisoning, it is describing a compound given at ten to a hundred times a supplement serving, often straight into a vein, to a patient who is already critically unwell. Extrapolating either the benefits or the harms from that setting to a 5 mg capsule taken with breakfast is not a small leap.

What the Methylene Blue Liver Studies Show — and What They Don’t

There are three kinds of evidence people cite here, and they are not equally strong.

Animal protection models. In a rat study published in International Immunopharmacology, Sprague-Dawley rats were poisoned with paraquat, a herbicide that causes severe oxidative liver damage. Rats given methylene blue at 2 mg/kg by intraperitoneal injection two hours after the poison showed less histological damage, lower serum alkaline phosphatase and alanine transaminase, less malondialdehyde, and higher superoxide dismutase, ATP and heme oxygenase-1. The authors attributed the effect to inhibition of mitochondrial permeability transition pore opening (Chen et al., 2015, PMID 25943564).

That is a genuinely interesting result, and it is worth being precise about what it is: rats, injected, acute chemical poisoning, one toxin. It is evidence that the compound has antioxidant activity in liver tissue under extreme stress. It is not evidence that a daily capsule treats or protects a human liver. If the antioxidant mechanism is what interests you, the broader piece on how to reduce oxidative stress puts it in context alongside the interventions with much stronger human data.

Clinical case reports. A report in Transplantation Proceedings described methylene blue used during postoperative recovery after liver transplantation (Roma et al., 2010, PMID 20304203). A single case report sits at the bottom of the evidence hierarchy. It tells you something was tried and observed once. It does not establish an effect.

What is missing. There is no long-term controlled human trial of low-dose oral methylene blue with liver enzymes or liver imaging as endpoints. Nothing published supports using it to treat fatty liver disease, cirrhosis or any chronic liver condition, and no reputable source claims otherwise. Anyone selling it on that basis is ahead of the science.

It is worth understanding why search results for methylene blue liver questions look the way they do. The compound has a long clinical history in acute hospital medicine, so the indexed literature is dominated by intensive care, transplantation and toxicology. Those papers are easy to find and easy to misread. A study titled “methylene blue attenuates acute liver injury” gets quoted as though it were a supplement trial, when the animals in it were poisoned with a herbicide first. The absence of low-dose oral data is not the same as evidence of a problem — but it is also not the same as evidence of a benefit, and the two get conflated constantly.

Who Should Be Cautious About Methylene Blue and Liver Health

Caution here is mostly about clearance and interactions rather than direct organ damage.

• Reduced liver function. If the liver is not clearing compounds at a normal rate, whatever you take stays in circulation longer. That is a reason to have the conversation with a clinician before starting, and to stay at the bottom of the dose range if you do.
• G6PD deficiency. This is the clearest contraindication of all, and it has nothing to do with the liver — it concerns red blood cells and the risk of haemolysis. The dedicated explainer on methylene blue and G6PD deficiency covers why.
• Serotonergic medication. Methylene blue inhibits monoamine oxidase A. Combined with SSRIs, SNRIs or MAOIs it can contribute to serotonin toxicity. This is the interaction that matters most, and the methylene blue drug interactions guide lists the drug classes involved.
• Heavy or regular alcohol intake. No study has tested the combination, but a liver already carrying a substantial workload is a reason to be conservative rather than casual.

One nuance worth holding onto: because elimination runs through both the kidneys and the liver, impairment in either organ shifts the load onto the other. That is the actual mechanism behind most methylene blue liver cautions, and it is also why the caution scales with dose. At 5 mg the reserve capacity involved is large. At the doses used in the clinical literature it is not, which is precisely why hospital use is supervised and a supplement serving is not the same conversation.

What would genuinely warrant stopping and getting checked is not subtle: yellowing of the skin or eyes, dark urine that is not the harmless blue-green tint methylene blue itself produces, persistent right-upper-abdominal pain, or unexplained nausea and fatigue that builds over days. None of these are expected effects. They are the general signs of liver trouble from any cause, and they deserve a doctor rather than a dose adjustment.

If you are not sure which of these applies to you, the checklist in who should not take methylene blue is the faster way to find out than working through the pharmacology.

Practical Ways to Keep Methylene Blue Liver Load Low

Four things make a measurable difference, and one of them is about the product rather than the protocol.

1. Stay at the low end. Most of the cognitive and energy research people are chasing sits at low milligram doses. Going higher does not scale the benefit and does increase everything the body has to clear.
2. Take it with food. NooBlue’s label suggests one capsule daily with food, in the morning or early afternoon. That is also the pattern most likely to keep the dose steady rather than spiking.
3. Know what else you are taking. Interactions, not the liver, are where the real risk lives. That includes ordinary things — the piece on methylene blue and coffee covers the most common daily pairing, and whether methylene blue is safe to take daily covers frequency.
4. Buy pharmaceutical-grade, not dye-grade. This is the liver-relevant one. Industrial and laboratory methylene blue is manufactured to stain fabric and tissue samples, not to be swallowed, and can carry heavy-metal and contaminant residues that a body genuinely does have to process. Grade is not marketing language; it is the difference between a defined impurity profile and an undefined one.

That last point is the reason NooBlue publishes a Certificate of Analysis for every batch. The NooBlue Methylene Blue Capsules are USP grade with a verified COA and precision dosing at exactly 5 mg per capsule — $37.99 for 60 capsules, which works out at $0.63 per one-capsule serving. If you prefer to control the dose more finely, the NooBlue Methylene Blue Solution 1% is $29.99 for 50 ml, about $0.30 per 0.5 ml serving. Shop Liquid or capsules depending on how granular you want to be — the tablets and liquid formats compared piece walks through the trade-offs. Both ship worldwide, including the UK and Europe.

Methylene Blue and Liver Health: Common Questions

Does methylene blue harm the liver?

No published human study has shown liver injury from oral methylene blue at supplement serving sizes. The liver participates in clearing the compound, and in animal models it has actually reduced markers of chemically induced liver damage. The honest caveat is that no long-term trial has specifically monitored liver endpoints in people taking low daily doses, so the position is “no evidence of harm” rather than “proven safe indefinitely.” Alcohol loads the same organ, so if you drink regularly that overlap matters more than the dye does — see what the research says about mixing methylene blue and alcohol.

Is methylene blue good for fatty liver?

There is no clinical evidence supporting methylene blue as a treatment for fatty liver disease. The animal work showing hepatic protection used an acute poisoning model, not chronic fatty liver, and used injected doses far above any supplement serving. Anyone marketing it for fatty liver is extrapolating well beyond the data.

Can methylene blue raise liver enzymes?

There is no established signal of methylene blue raising alanine transaminase or alkaline phosphatase at oral supplement doses. In the rat paraquat study, methylene blue lowered both enzymes when they had been driven up by the toxin. If you already monitor liver enzymes for another reason, keep monitoring them and tell whoever ordered the test what you are taking.

Who should not take methylene blue?

People with G6PD deficiency, anyone taking serotonergic medication such as SSRIs, SNRIs or MAOIs, people who are pregnant or breastfeeding, and anyone with significant kidney or liver impairment who has not discussed it with a clinician. Liver impairment appears on that list because of slower clearance, not because the compound is known to damage liver tissue. Slower clearance just means the compound lingers longer — how long methylene blue stays in your system sets out the timeline.

This article is for educational purposes only and is not medical advice. Methylene blue is a potent compound; talk to a qualified healthcare professional before starting any new supplement, especially if you take medication (notably SSRIs or MAOIs) or have a health condition.